Fe³⁺-binding transferrin nanovesicles encapsulating sorafenib induce ferroptosis in hepatocellular carcinoma.

ABSTRACT:

Background

Ferroptosis, iron-dependent cell death, is an established mechanism for cancer suppression, particularly in hepatocellular carcinoma (HCC). Sorafenib (SOR), a frontline drug for the treatment of HCC, induces ferroptosis by inhibiting the Solute Carrier family 7 member 11 (SLC7A11), with inadequate ferroptosis notably contributing to SOR resistance in tumor cells.

Methods

To further verify the biological targets associated with ferroptosis in HCC, an analysis of the Cancer Genome Atlas (TCGA) database was performed to find a significant co-upregulation of SLC7A11 and transferrin receptor (TFRC), Herein, cell membrane-derived transferrin nanovesicles (TF NVs) coupled with Fe³⁺ and encapsulated SOR (SOR@TF-Fe³⁺ NVs) were established to synergist

SUBMITTER: Xiao Y 

PROVIDER: S-EPMC10314404 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature